CLAIMS

1. A compound of th Formula I



Formula I

a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

wherein R^1 is hydrogen, Y, W-X or W-Y;

wherein W is a carbonyl, thiocarbonyl, sulfinyl or sulfonyl;

X is -O-Y, -S-Y, -N(H)-Y or $-N-(Y)_2$;

wherein Y for each occurrence is independently Z or a fully saturated, partially unsaturated or fully unsaturated one to ten membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono-, or di-substituted with oxo, and said carbon chain is optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated thr to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independ ntly with halo, (C_2-C_6)alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino, said (C_1-C_6)alkyl substituent is also optionally substituted with from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to seven membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen, wherein said R^2 ring is optionally attached through (C_1-C_4)alkyl;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, (C_2-C_6)alkenyl, (C_1-C_6) alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, oxo or (C_1-C_6)alkyloxycarbonyl;

with the proviso that R^2 is not methyl;

R^3 is hydrogen or Q;

wherein Q is a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-

substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrog n is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V;

wherein V is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said V substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxamoyl, mono-N- or di-N,N-(C_1-C_6) alkylcarboxamoyl, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl or (C_2-C_6)alkenyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino, said (C_1-C_6)alkyl or (C_2-C_6)alkenyl substituents are also optionally substituted with from one to nine fluorines;

R^4 is Q^1 or V^1;

wherein Q^1 a fully saturated, partially unsaturated or fully unsaturated one to six membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected from oxygen, sulfur and nitrogen and said carbon is optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon chain is optionally mono-substituted with V^1;

wherein V^1 is is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V^1 substituent is optionally mono-, di-, tri-, or tetra-substituted independently with halo, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, amino, nitro,

cyano, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent is optionally mono-substituted with oxo, said (C_1-C_6)alkyl substituent is also optionally substituted with from one to nine fluorines;

wherein either R^3 must contain V or R^4 must contain V^1;

R^5, R^6, R^7 and R^8 are each independently hydrogen, a bond, nitro or halo wherein said bond is substituted with T or a partially saturated, fully saturated or fully unsaturated (C_1-C_{12}) straight or branched carbon chain wherein carbon, may optionally be replaced with one or two heteroatoms selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with hydroxy, said carbon is optionally mono-substituted with oxo, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo, and said carbon is optionally mono-substituted with T;

wherein T is a partially saturated, fully saturated or fully unsaturated three to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino, said (C_1-C_6)alkyl substituent is also optionally substituted with from one to nine fluorines; and

wherein R^5 and R^6, or R^6 and R^7, and/or R^7 and R^8 may also be taken together and can form at least one four to eight membered ring that is partially saturated or fully unsaturated optionally having one to three heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring or rings formed by R^5 and R^6, or R^6 and R^7, and/or R^7 and R^8 are optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, (C_1-C_4)alkylsulfonyl, (C_2-C_6)alkenyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino, said (C_1-C_6)alkyl substituent is also optionally substituted with from one to nine fluorines;

with the proviso that when R^2 is carboxyl or (C_1-C_4)alkylcarboxyl, then R^1 is not hydrogen.

2. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta:

R^1 is W-X ;

W is carbonyl, thiocarbonyl or $-SO_2-$;

X is -O-Y-, S-Y-, N(H)-Y- or $-N-(Y)_2-$;

Y for each occurrence is independently Z or (C_1-C_4)alkyl, said (C_1-C_4)alkyl optionally substituted with from one to nine fluorines or hydroxy, or said (C_1-C_4)alkyl optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, nitro, cyano, oxo, or (C_1-C_6)alkyloxycarbonyl, said (C_1-C_4)alkyl is optionally substituted with from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substitut d with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-

substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrogen;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, $(C_1$-$C_6)$alkoxy or $(C_1$-$C_6)$alkoxycarbonyl;

R^3 is Q-V wherein Q is $(C_1$-$C_4)$alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, $(C_1$-$C_6)$alkyl, hydroxy, $(C_1$-$C_6)$alkoxy, nitro, cyano or oxo wherein said $(C_1$-$C_6)$alkyl substituent optionally has from one to nine fluorines;

R^4 is $(C_1$-$C_4)$alkyl;

R^6 and R^7 are each independently H, halo, T or $(C_1$-$C_6)$alkyl, said $(C_1$-$C_6)$alkyl optionally having from one to nine fluorines or said $(C_1$-$C_6)$alkyl is optionally mono-substituted with T;

wherein T is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, $(C_1$-$C_6)$alkyl, hydroxy, $(C_1$-$C_6)$alkoxy, $(C_1$-$C_4)$alkylthio, amino, oxo, carboxy, $(C_1$-$C_6)$alkyloxycarbonyl, mono-N- or di-N,N-$(C_1$-$C_6)$alkylamino wherein said $(C_1$-$C_6)$alkyl substituent optionally has from one to nine fluorines; and

R^5 and R^8 are H,

or a pharmaceutically acceptable salt thereof.

3. A compound as recited in claim 2 wherein

W is carbonyl;

X is O-Y wherein Y is $(C_1$-$C_4)$alkyl, said $(C_1$-$C_4)$alkyl substituent optionally substituted with from one to nine fluorines or hydroxy;

Q is $(C_1$-$C_4)$alkyl and V is phenyl, pyridinyl, or pyrimidinyl;

wherein said V ring is optionally mono-, di- or tri-substituted independently with halo, $(C_1$-$C_6)$alkyl, hydroxy, $(C_1$-$C_6)$alkoxy, nitro, cyano or

oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^2 is a fully saturated (C_1-C_4) straight or branched carbon chain; or said R^2 is a fully saturated three to five membered ring; wherein said R^2 chain or ring is optionally mono-, di- or tri-substituted independently with halo; and

R^6 and R^7 are each independently hydrogen, halo or (C_1-C_6)alkyl, said (C_1-C_6)alkyl optionally having from one to nine fluorines;

or a pharmaceutically acceptable salt thereof.

4. A compound as recited in claim 3 wherein

Q is methyl and V is phenyl or pyridinyl;

wherein said V ring is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_2)alkyl, or nitro wherein said (C_1-C_2)alkyl optionally has from one to five fluorines,

or a pharmaceutically acceptable salt thereof.

5. A compound as recited in claim 1 wherein said compound is

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-isopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-cyclopropyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 2-cyclopropyl-4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester; or

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester,

or a pharmaceutically acceptable salt of said compounds.

6. A compound as recited in claim 1 wherein said compound is

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;
[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester;
[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;
[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester; or
[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester,
or a pharmaceutically acceptable salt thereof.

7. A compound as recited in claim 4 wherein
Y is isopropyl;
R^2 is isopropyl;
R^3 is 3,5-bis-trifluoromethylphenylmethyl;
R^4 is methyl;
R^6 is trifluoromethyl; and
R^7 is H, or a pharmaceutically acceptable salt thereof.

8. A compound as recited in claim 4 wherein
Y is isopropyl;
R^2 is cyclopropyl;
R^3 is 3,5-bis-trifluoromethylphenylmethyl;
R^4 is methyl;
R^6 is chloro; and
R^7 is H, or a pharmaceutically acceptable salt thereof.

9. A compound as recited in claim 4 wh rein

Y is isopropyl;

R^2 is cyclopropyl;

R^3 is 3,5-dichlorophenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

10. A compound as recited in claim 4 wherein

Y is tert-butyl;

R^2 is cyclopropyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

11. A compound as recited in claim 4 wherein

Y is isopropyl;

R^2 is cyclopropyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

12. A compound as recited in claim 4 wherein

Y is isopropyl;

R^2 is cyclobutyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

13. A compound as recited in claim 4 wherein

Y is isopropyl;

R^2 is ethyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptabl salt thereof.

14. A compound as recited in claim 4 wherein

Y is isopropyl;

R^2 is methoxymethyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

15. A compound as recited in claim 4 wherein

Y is 2-hydroxyethyl;

R^2 is ethyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

16. A compound as recited in claim 4 wherein

Y is ethyl;

R^2 is cyclopropyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

17. A compound as recited in claim 4 wherein

Y is ethyl;

R^2 is ethyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

18. A compound as recited in claim 4 wherein

Y is n-propyl;

R^2 is cyclopropyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

19. A compound as recited in claim 4 wherein

Y is n-propyl;

R^2 is ethyl;

R^3 is 3,5-bis-trifluoromethylphenylmethyl;

R^4 is methyl;

R^6 is trifluoromethyl; and

R^7 is H, or a pharmaceutically acceptable salt thereof.

20. A compound selected from the group consisting of

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-isopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-6-chloro-2-cyclopropyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 2-cyclopropyl-4-[(3,5-dichloro-benzyl)-methoxycarbonyl-amino]-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid tert-butyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclobutyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-methoxymethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid isopropyl ester;

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid 2-hydroxy-ethyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid thyl ester;

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid ethyl ester;

[2S,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-cyclopropyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester; and

[2R,4S] 4-[(3,5-bis-trifluoromethyl-benzyl)-methoxycarbonyl-amino]-2-ethyl-6-trifluoromethyl-3,4-dihydro-2H-quinoline-1-carboxylic acid propyl ester,

or a pharmaceutically acceptable salt thereof.

21. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta;

R^1 is W-X ;

W is carbonyl, thiocarbonyl or sulfonyl;

X is -O-Y-, S-Y-, N(H)-Y- or -N-$(Y)_2$-;

Y for each occurrence is independently Z or $(C_1$-$C_4)$alkyl, said $(C_1$-$C_4)$alkyl optionally having from one to nine fluorines or said $(C_1$-$C_4)$alkyl optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, $(C_1$-$C_4)$alkyl, $(C_1$-$C_4)$alkoxy, $(C_1$-$C_4)$alkylthio, nitro, cyano, oxo, or $(C_1$-$C_6)$alkyloxycarbonyl, said $(C_1$-$C_4)$alkyl substituent optionally substituted with from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-

substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated thre to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrogen;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy or (C_1-C_6)alkoxycarbonyl;

R^3 is Q-V wherein Q is (C_1-C_4)alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, nitro, cyano or oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^4 is (C_1-C_4)alkyl; and

R^5 and R^6, or R^6 and R^7, or R^7 and R^8 are taken together and form one ring that is a partially saturated or fully unsaturated five or six membered ring optionally having one to two heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring formed by R^5 and R^6, or R^6 and R^7, or R^7 and R^8 is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkylsulfonyl, (C_2-C_4)alkenyl, hydroxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_4)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino wherein said (C_1-C_4)alkyl substituent is optionally mono-, di- or tri-substituted independently with hydroxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_4)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino or said (C_1-C_4)alkyl substituent optionally has from one to nine fluorines;

provided that the R^5, R^6, R^7 and/or R^8, as the case may be, that do not form the ring are hydrogen,

or a pharmaceutically acceptable salt thereof.

22. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta;

R^1 is W-Y ;

W is carbonyl, thiocarbonyl or sulfonyl;

Y is (C_1-C_6)alkyl, said (C_1-C_6)alkyl optionally having from one to nine fluorines or said (C_1-C_6)alkyl optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, nitro, cyano, oxo, or (C_1-C_6)alkyloxycarbonyl, said (C_1-C_4)alkyl optionally substituted with from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrogen;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy or (C_1-C_6)alkoxycarbonyl;

R^3 is Q-V wherein Q is (C_1-C_4)alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, nitro, cyano or oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^4 is (C_1-C_4)alkyl;

R^6 and R^7 are each independently (C_1-C_6)alkyl or (C_1-C_6)alkoxy, said (C_1-C_6)alkyl or (C_1-C_6)alkoxy substituents optionally having from one to nine

fluorines or said (C_1-C_6)alkoxy or (C_1-C_6)alkyl substituents optionally mono-substitut d with T;

wherein T is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

or R^6 and R^7 are taken together and form one ring that is a partially saturated or fully unsaturated five or six membered ring optionally having one to two heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring formed by R^6 and R^7 is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkylsulfonyl, (C_2-C_4)alkenyl, hydroxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_4)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino wherein said (C_1-C_4)alkyl substituent optionally has from one to nine fluorines; and

R^5 and R^8 are H,

or a pharmaceutically acceptable salt thereof.

23. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta;

R^1 is Y;

Y is (C_2-C_6)alkenyl or (C_1-C_6)alkyl, said (C_2-C_6)alkenyl or (C_1-C_6)alkyl optionally having from one to nine fluorines or said (C_2-C_6)alkenyl or (C_1-C_6)alkyl optionally mono-substituted with Z;

wherein Z is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, nitro,

cyano, oxo, or (C_1-C_6)alkyloxycarbonyl, said (C_1-C_4)alkyl substitu nt optionally substituted with from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrogen;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy or (C_1-C_6)alkoxycarbonyl;

R^3 is Q-V wherein Q is (C_1-C_4)alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, nitro, cyano or oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^4 is (C_1-C_4)alkyl;

R^6 and R^7 are each independently (C_1-C_6)alkyl or (C_1-C_6)alkoxy, said (C_1-C_6)alkyl or (C_1-C_6)alkoxy substituents optionally having from one to nine fluorines or said (C_1-C_6)alkoxy or (C_1-C_6)alkyl substituents optionally mono-substituted with T,

wherein T is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-

C_6)alkylamino wherein said (C_1-C_6)alkyl substituent optionally has from one to nin fluorin s;

or R^6 and R^7 are taken together and form one ring that is a partially saturated or fully unsaturated five or six membered ring optionally having one to two heteratoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring formed by R^6 and R^7 is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkylsulfonyl, (C_2-C_4)alkenyl, hydroxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_4)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino wherein said (C_1-C_4)alkyl substituent optionally has from one to nine fluorines; and

R^5 and R^8 are H, or a pharmaceutically acceptable salt thereof.

24. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta;

R^1 is Z;

Z is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, nitro, cyano, oxo, or (C_1-C_6)alkyloxycarbonyl, said (C_1-C_4)alkyl substituent optionally having one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrog n;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independ ntly with halo, hydroxy, (C_1-C_6)alkoxy or (C_1-C_6)alkoxycarbonyl;

R^3 is Q-V wherein Q is (C_1-C_4)alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, nitro, cyano or oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^4 is (C_1-C_4)alkyl;

R^6 and R^7 are each independently (C_1-C_6)alkyl or (C_1-C_6)alkoxy, said (C_1-C_6)alkyl or (C_1-C_6)alkoxy substituents optionally having from one to nine fluorines or said (C_1-C_6)alkoxy or (C_1-C_6)alkyl substituents optionally mono-substituted with T;

wherein T is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

or R^6 and R^7 are taken together and form one ring that is a partially saturated or fully unsaturated five or six membered ring optionally having one to two heteratoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring formed by R^6 and R^7 is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkylsulfonyl, (C_2-C_4)alkenyl, hydroxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_4)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino wherein said (C_1-C_4)alkyl substituent optionally has from one to nine fluorines; and

R^5 and R^8 are H, or a pharmaceutically acceptable salt thereof.

25. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta:

R^1 is W-Z;

W is carbonyl, thiocarbonyl or sulfonyl;

Z is a partially saturat d, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, nitro, cyano, oxo, or (C_1-C_6)alkyloxycarbonyl, said (C_1-C_4)alkyl substituent optionally having from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrogen;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy or (C_1-C_6)alkoxycarbonyl;

R^3 is Q-V wherein Q is (C_1-C_4)alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, nitro, cyano or oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^4 is (C_1-C_4)alkyl;

R^6 and R^7 are each independently (C_1-C_6)alkyl or (C_1-C_6)alkoxy, said (C_1-C_6)alkyl or (C_1-C_6)alkoxy substituents optionally having from one to nine

fluorines or said (C_1-C_6)alkoxy or (C_1-C_6)alkyl substituents optionally mono-substituted with T;

wherein T is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to two heteroatoms s lected independently from oxygen, sulfur and nitrogen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_6)alkylamino wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

or R^6 and R^7 are taken together and form one ring that is a partially saturated or fully unsaturated five or six membered ring optionally having one to two heteroatoms independently selected from nitrogen, sulfur and oxygen;

wherein said ring formed by R^6 and R^7 is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkylsulfonyl, (C_2-C_4)alkenyl, hydroxy, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, amino, nitro, cyano, oxo, carboxy, (C_1-C_4)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-C_4)alkylamino wherein said (C_1-C_4)alkyl substituent optionally has from one to nine fluorines; and

R^5 and R^8 are H, or a pharmaceutically acceptable salt thereof

26. A compound as recited in claim 1 wherein

R^2 is beta;

the C^4 nitrogen is beta;

R^1 is W-X;

W is carbonyl, thiocarbonyl or sulfonyl;

X is -O-Y-, S-Y-, N(H)-Y- or -N-$(Y)_2$-;

Y for each occurrence is independently Z or (C_1-C_4)alkyl, said (C_1-C_4)alkyl substituent optionally having from one to nine fluorines or said (C_1-C_4)alkyl optionally mono-substituted with Z

wherein Z is a partially saturated, fully saturated or fully unsaturated three to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said Z substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkylthio, nitro,

cyano, oxo, or (C_1-C_6)alkyloxycarbonyl, said (C_1-C_4)alkyl substituent optionally substitut d with from one to nine fluorines;

R^2 is a partially saturated, fully saturated or fully unsaturated one to four membered straight or branched carbon chain wherein the carbons, other than the connecting carbon, may optionally be replaced with one heteroatom selected independently from oxygen, sulfur and nitrogen wherein said carbon atoms are optionally mono-, di- or tri-substituted independently with halo, said carbon is optionally mono-substituted with oxo, said carbon is optionally mono-substituted with hydroxy, said sulfur is optionally mono- or di-substituted with oxo, said nitrogen is optionally mono- or di-substituted with oxo; or said R^2 is a partially saturated, fully saturated or fully unsaturated three to five membered ring optionally having one heteroatom selected independently from oxygen, sulfur and nitrogen;

wherein said R^2 ring is optionally mono-, di- or tri-substituted independently with halo, hydroxy, (C_1-C_6)alkoxy or (C_1-C_6)alkoxycarbonyl;

R^3 is Q-V wherein Q is (C_1-C_4)alkyl and V is a five or six membered partially saturated, fully saturated or fully unsaturated ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said V ring is optionally mono-, di-, tri- or tetra-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, nitro, cyano or oxo wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines;

R^4 is (C_1-C_4)alkyl;

at least one of R^6 and R^7 is (C_1-C_4)alkoxy and at least one of R^6 and R^7 is (C_1-C_6)alkyl, said (C_1-C_6)alkyl and (C_1-C_4)alkoxy substituents optionally having from one to nine fluorines or said (C_1-C_6)alkyl and (C_1-C_4)alkoxy substituents optionally mono-substituted with T,

wherein T is a partially saturated, fully saturated or fully unsaturated five to six membered ring optionally having one to two heteroatoms selected independently from oxygen, sulfur and nitrogen;

wherein said T substituent is optionally mono-, di- or tri-substituted independently with halo, (C_1-C_6)alkyl, hydroxy, (C_1-C_6)alkoxy, (C_1-C_4)alkylthio, amino, oxo, carboxy, (C_1-C_6)alkyloxycarbonyl, mono-N- or di-N,N-(C_1-

C_6)alkylamino wherein said (C_1-C_6)alkyl substituent optionally has from one to nine fluorines; and

R^5 and R^8 are H, or a pharmaceutically acceptable salt thereof.

27. A method for treating atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female) by administering to a mammal in need of such treatment an atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia treating amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug.

28. A method as recited in claim 27 wherein atherosclerosis is treated.

29. A method as recited in claim 27 wherein peripheral vascular disease is treated.

30. A method as recited in claim 27 wherein dyslipidemia is treated.

31. A method as recited in claim 27 wherein hyperbetalipoproteinemia is treated.

32. A method as recited in claim 27 wherein hypoalphalipoproteinemia is treated.

33. A method as recited in claim 27 wherein hypercholesterolemia is treated.

34. A method as recited in claim 27 wherein hypertriglyceridemia is treated.

35. A method as recited in claim 27 wherein cardiovascular disorders are treated.

36. A pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier.

37. A pharmaceutical composition for the treatment of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial

infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal which comprise a therapeutically effective amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier.

38. A pharmaceutical composition for the treatment of atherosclerosis in a mammal which comprises an atherosclerosis treating amount of a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier.

39. A pharmaceutical combination composition comprising: a therapeutically effective amount of a composition comprising

a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug;

a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant; and

a pharmaceutical carrier.

40. A pharmaceutical combination composition as recited in claim 39 wherein the second compound is an HMG-CoA reductase inhibitor or a MTP/Apo B secretion inhibitor.

41. A pharmaceutical combination composition as recited in claim 39 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or rivastatin.

42. A method for treating atherosclerosis in a mammal comprising administering to a mammal in need of treatment thereof;

a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug; and

a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a

cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant

wh rein the amounts of first and second compounds result in a therapeutic effect.

43. A method for treating atherosclerosis as recited in claim 42 wherein the second compound is an HMG-CoA reductase inhibitor or a MTP/Apo B secretion inhibitor.

44. A method for treating atherosclerosis as recited in claim 42 wherein the second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or rivastatin.

45. A kit comprising:

a. a first compound, said first compound being a compound of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug and a pharmaceutically acceptable carrier in a first unit dosage form;

b. a second compound, said second compound being an HMG CoA reductase inhibitor, an MTP/Apo B secretion inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant and a pharmaceutically acceptable carrier in a second unit dosage form; and

c. means for containing said first and second dosage forms

wherein the amounts of first and second compounds result in a therapeutic effect.

46. A kit as recited in claim 45 wherein said second compound is an HMG-CoA reductase inhibitor or an MTP/Apo B secretion inhibitor.

47. A kit as recited in claim 45 wherein said second compound is lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin or rivastatin.